List of Excipients in Branded Drug DIFLORASONE DIACETATE OINT

« Back to Dashboard

Generic Drugs Containing DIFLORASONE DIACETATE OINT

Company	Ingredient	NDC	Excipient
Sola Pharmaceuticals	diflorasone diacetate ointment	70512-031	GLYCERYL MONOSTEARATE
Sola Pharmaceuticals	diflorasone diacetate ointment	70512-031	PETROLATUM
Sola Pharmaceuticals	diflorasone diacetate ointment	70512-031	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in DIFLORASONE DIACETATE OINT?

# Of NDCs	Excipient
1	GLYCERYL MONOSTEARATE
1	PETROLATUM
1	PROPYLENE GLYCOL

Last updated: October 6, 2026

Diflorasone diacetate ointment is a mature, prescription-only topical corticosteroid opportunity. The active ingredient and basic petrolatum-based formulation are unlikely to support meaningful exclusivity in the United States, but commercial value remains in reliable generic supply, differentiated semisolid performance, private-label distribution, and formulation improvements that reduce greasiness or improve patient adherence. The principal technical barrier is proving pharmaceutical equivalence and comparable topical performance, not discovering new active-ingredient IP.

Diflorasone Diacetate Ointment Excipient Strategy, Patent Position, and Commercial Opportunities

What is diflorasone diacetate ointment?

Diflorasone diacetate ointment is a 0.05% topical corticosteroid used for corticosteroid-responsive dermatoses, including inflammatory and pruritic skin conditions. The ointment is generally classified as a very-high-potency or super-potent topical corticosteroid in US potency systems.[1]

Attribute	Diflorasone diacetate ointment
Active ingredient	Diflorasone diacetate
Strength	0.05%
Dosage form	Topical ointment
Route	Cutaneous
Regulatory status	Prescription drug in the United States
Primary reference product	Florone and equivalent products
Therapeutic class	Topical corticosteroid
Typical commercial category	Generic dermatology product
Biosimilar pathway	Not applicable
Primary development route	ANDA or, in limited cases, 505(b)(2)

The product is intended for short-duration treatment. US labeling limits the amount used and cautions against prolonged treatment, extensive application, occlusion, and application to sensitive areas such as the face, groin, and axillae.[1]

What excipients are used in diflorasone diacetate ointment?

The conventional ointment platform uses a hydrophobic base consisting principally of mineral oil and white petrolatum. The reference product labeling identifies these materials as inactive ingredients for the ointment formulation.[1]

Excipient	Primary function	Commercial and technical relevance
White petrolatum	Continuous oleaginous base, occlusivity, emolliency	Provides strong barrier effect but can feel greasy
Mineral oil	Viscosity adjustment, spreading, emolliency	Controls workability and reduces petrolatum stiffness
Antioxidant, if used	Limits oxidation of susceptible components	Requires justification and label consistency
Chelator, if used	Controls trace-metal catalyzed degradation	More relevant to complex or partially aqueous systems
Preservative, if used	Microbial control	Usually unnecessary in anhydrous ointments, but depends on water activity and packaging

A simple petrolatum-mineral-oil system has a low excipient risk profile. It is anhydrous, generally does not require a conventional antimicrobial preservative, and uses excipients with extensive pharmaceutical history.

The main development risks are physical rather than chemical:

• crystal or particle growth of diflorasone diacetate;
• poor content uniformity at the low drug concentration;
• phase separation during storage;
• excessive drag during application;
• gritty texture;
• inconsistent extrusion from the package;
• changes in viscosity caused by heat exposure;
• drug migration into the package;
• differences in skin residence and occlusion relative to the reference product.

Which excipient strategy is best for a generic diflorasone diacetate ointment?

The lowest-risk strategy is a close qualitative and quantitative match to the reference ointment using white petrolatum and mineral oil. This approach minimizes formulation novelty and simplifies the pharmaceutical-equivalence argument.

Strategy 1: Reference-matched petrolatum ointment

A reference-matched base is the strongest option when the objective is rapid ANDA development.

Advantages include:

• limited excipient precedent;
• straightforward anhydrous manufacturing;
• low preservative burden;
• familiar regulatory profile;
• low raw-material cost;
• broad compatibility with aluminum tubes and laminate packaging.

The formulation must still demonstrate acceptable drug distribution, assay, impurities, rheology, appearance, and stability. Matching excipient names alone does not establish equivalent performance.

Strategy 2: Lower-grease ointment

A manufacturer can reduce perceived greasiness by modifying the ratio of petrolatum to liquid hydrocarbon or by using compatible semisolid hydrocarbons. This may improve patient acceptance but can alter occlusion, spreadability, drug release, and residence time.

This approach has commercial value where adherence is limited by the feel of traditional ointments. It also creates a greater need for comparative performance testing.

Strategy 3: Absorption-enhanced ointment

Penetration enhancers, surfactants, or solvent systems could increase delivery into the stratum corneum. This strategy has a higher regulatory and safety burden. For a super-potent corticosteroid, enhanced penetration can increase the risk of local atrophy, systemic absorption, and hypothalamic-pituitary-adrenal-axis suppression.

The commercial case is weak unless the formulation produces a measurable benefit in a defined patient population. A penetration-enhanced product may also create a new drug-product profile that is difficult to bridge to the reference product.

Strategy 4: Water-in-oil or emulsion ointment

An emulsion can improve cosmetic acceptability and washability. It may also require preservatives, emulsifiers, pH control, and more complex manufacturing.

The formulation becomes more vulnerable to:

• microbial contamination;
• emulsion instability;
• preservative sensitivity;
• pH-driven degradation;
• container-closure interactions;
• manufacturing scale-up failure.

For a generic product, an emulsion is usually a differentiation strategy rather than the lowest-cost regulatory route.

What regulatory pathway applies to diflorasone diacetate ointment?

A conventional generic diflorasone diacetate ointment would normally be submitted under an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to establish pharmaceutical equivalence and bioequivalence through the applicable FDA topical-product framework.[2]

Topical semisolid products may require a combination of:

• comparative composition data;
• assay and content-uniformity testing;
• rheology and viscosity testing;
• particle-size or drug-state characterization;
• in vitro release testing;
• in vitro permeation testing where relevant;
• product quality and stability data;
• comparative clinical endpoint studies, depending on FDA requirements.

FDA’s guidance for topical dermatological products recognizes that formulation changes can affect local availability even when the active ingredient concentration is unchanged.[3]

The development team should treat the following as critical quality attributes:

Quality attribute	Why it matters
Assay	Confirms labeled strength
Content uniformity	Controls dose variability across the tube
Drug crystallinity	Affects release and skin delivery
Particle size	Influences uniformity and dissolution
Rheology	Controls extrusion and patient application
In vitro release rate	Supports product comparability
Appearance and texture	Influences adherence and market acceptance
Water activity	Supports microbial-risk assessment
Stability	Detects phase, assay, impurity, and texture changes

What patents protect diflorasone diacetate ointment?

The original active-ingredient and early product patents for diflorasone diacetate are expected to be expired. The commercial patent opportunity therefore lies primarily in later formulation, packaging, manufacturing, or use claims rather than in the base molecule.

Potential patent categories include:

1. Formulation patents covering a specific hydrocarbon ratio, emulsion structure, penetration enhancer, particle-size distribution, or rheological profile.
2. Method-of-use patents covering treatment of a defined dermatologic condition, dosing regimen, or duration of use.
3. Manufacturing patents covering micronization, dispersion, homogenization, deaeration, filling, or controlled thermal processing.
4. Packaging patents covering tube materials, metered delivery, applicators, or contamination-control systems.
5. Combination-product patents covering diflorasone diacetate with another active ingredient or delivery technology.

A basic diflorasone diacetate ointment containing mineral oil and white petrolatum is unlikely to produce durable composition-of-matter exclusivity. Any new patent position would require a non-obvious technical distinction and evidence of improved performance.

What is the Orange Book status of diflorasone diacetate ointment?

FDA Orange Book analysis should distinguish between:

• the reference listed drug;
• approved generic ointments;
• any listed patents;
• pediatric exclusivity;
• regulatory exclusivity;
• product-specific labeling differences.

Diflorasone diacetate ointment is a legacy topical product. The primary commercial route for a new equivalent is an ANDA, with patent certification obligations determined by the Orange Book record for the relevant reference product.[4]

Exclusivity category	Relevance to diflorasone diacetate ointment
New chemical entity exclusivity	Not available for this mature active ingredient
Five-year NCE exclusivity	Expired or unavailable
Three-year clinical-investigation exclusivity	Possible only for qualifying new changes
Orphan exclusivity	Not inherent to the product
Pediatric exclusivity	No general assumption should be made
Patent term extension	Unlikely to create current protection for the legacy product
Biosimilar exclusivity	Not applicable
ANDA market exclusivity	Depends on qualifying first-filer status and listed patents

A company should not assume that a generic product is blocked merely because a historical product patent existed. The relevant issue is whether an unexpired, enforceable, listed patent currently creates an ANDA certification or launch constraint.

When does diflorasone diacetate ointment lose exclusivity?

The molecule and conventional ointment technology are mature. Any original exclusivity associated with the active ingredient or initial product approval is no longer the principal commercial barrier.

Current launch timing depends on:

• FDA approval of the ANDA;
• patent certifications;
• any first-filer litigation;
• supply readiness;
• manufacturing-site qualification;
• contract pharmacy and wholesaler access;
• payer substitution and formulary placement.

For a conventional generic without blocking patents, the principal risk is regulatory execution rather than patent expiry. A Paragraph IV challenge would be relevant only if the reference product has an unexpired listed patent that the applicant seeks to invalidate or avoid.

Are there Paragraph IV challenges or litigation risks?

No broad biosimilar risk exists because diflorasone diacetate is a small-molecule drug, not a biologic. Generic applicants face ordinary Hatch-Waxman risks.

Potential litigation triggers include:

• a Paragraph IV certification against a listed formulation or method-of-use patent;
• allegations of infringement based on a formulation patent;
• trade-secret claims involving manufacturing parameters;
• antitrust claims involving delayed generic entry;
• product-liability claims based on potency, labeling, or skin atrophy;
• trademark or trade-dress disputes involving legacy branded products.

For a simple hydrocarbon ointment, patent litigation risk is generally lower than for complex topical products with proprietary delivery systems. The risk increases materially if a developer uses a novel enhancer, nanostructured carrier, controlled-release matrix, or proprietary applicator.

What manufacturing and IP barriers affect commercial entry?

The highest-value know-how is likely to be process-based rather than molecule-based.

Critical manufacturing controls

Diflorasone diacetate is present at a low concentration, so uniform distribution is a central manufacturing issue. Relevant controls include:

• premixing strategy;
• geometric dilution;
• particle-size control;
• temperature during incorporation;
• shear rate and mixing time;
• vacuum deaeration;
• bulk hold time;
• filling temperature;
• tube-fill accuracy;
• prevention of air entrapment.

The manufacturing process should prevent localized drug-rich or drug-poor regions. A visually uniform ointment can still fail content-uniformity or release testing.

Potential trade-secret assets

A company may protect the following as confidential know-how:

• order of excipient addition;
• heating and cooling profile;
• mixing energy;
• drug pre-dispersion method;
• deaeration conditions;
• bulk viscosity targets;
• fill-temperature window;
• packaging compatibility data;
• release-test acceptance ranges.

Trade secrets can protect process knowledge, but they do not prevent competitors from independently developing equivalent methods.

What commercial opportunities exist for diflorasone diacetate ointment?

The commercial opportunity is strongest in manufacturing efficiency and channel strategy, not premium pricing based solely on the active ingredient.

Generic and private-label supply

Potential customers include:

• large generic dermatology companies;
• regional pharmaceutical distributors;
• pharmacy private-label programs;
• government purchasing organizations;
• teledermatology pharmacies;
• specialty dermatology distributors.

A reliable supplier can compete through high service levels, low back-order rates, and multiple package sizes.

Formulation differentiation

Potential product concepts include:

• lower-grease ointment;
• improved spreadability;
• easier-to-wash semisolid;
• unit-dose or metered delivery;
• preservative-free alternative;
• tube optimized for accurate extrusion;
• co-packaged treatment regimen with moisturizer or barrier product.

Any differentiated product must preserve the therapeutic profile and comply with FDA requirements for topical equivalence.

Geographic opportunities

The United States provides a mature generic market governed by the FDA and ANDA process. Other opportunities may exist in Canada, Europe, Latin America, and selected emerging markets, but regulatory classification, reference-product requirements, naming conventions, and patent status differ by jurisdiction.

European commercialization would generally require compliance with national or centralized regulatory requirements applicable to topical medicinal products. Local market access depends on the approved reference product, pricing controls, reimbursement, and tender structures.

How does diflorasone diacetate ointment compare with competing topical corticosteroids?

Product class	Relative commercial position	Key comparison
Diflorasone diacetate ointment	High potency, mature generic	Strong efficacy perception, greasy vehicle
Clobetasol propionate ointment	Highly established super-potent competitor	Larger prescriber familiarity and broader generic supply
Betamethasone dipropionate ointment	High-potency competitor	Multiple formulations and established dermatology use
Fluocinonide ointment	High-potency competitor	Often used across a broad range of inflammatory dermatoses
Hydrocortisone ointment	Lower-potency alternative	Better suitability for sensitive areas and longer use
Tacrolimus ointment	Nonsteroidal alternative	Different safety, labeling, and reimbursement profile

Diflorasone diacetate competes against products with greater market familiarity. Its strongest positioning is as a dependable high-potency generic with consistent supply and acceptable vehicle performance.

What revenue exposure and launch scenarios are realistic?

Public revenue data for diflorasone diacetate ointment is generally not disclosed as a standalone product line. The market is likely fragmented across generic manufacturers, distributors, and private-label channels.

Launch scenario	Commercial outcome
Basic ANDA with reference-matched base	Lowest development risk, commodity pricing
Low-grease differentiated ointment	Higher development cost, potential adherence advantage
Novel delivery system	Higher IP potential, higher regulatory and clinical risk
Private-label supply agreement	Lower brand investment, predictable volume
Multiple-strength dermatology portfolio	Better sales coverage and contracting leverage
Single-product launch without channel access	High price and supply-chain risk

The most defensible business plan combines a low-risk reference-matched product with a second-generation vehicle or packaging concept. The first product supports market entry; the differentiated product creates a basis for customer retention and improved margin.

Key Takeaways

• Diflorasone diacetate ointment is a mature, prescription-only topical corticosteroid product.
• The conventional excipient platform is anhydrous and generally based on white petrolatum and mineral oil.
• The lowest-risk generic strategy is a reference-matched petrolatum ointment.
• The main technical risks are content uniformity, drug crystallinity, rheology, release rate, and package performance.
• Original active-ingredient exclusivity is not the principal barrier to entry.
• New commercial IP would most likely involve formulation, manufacturing, packaging, or defined use claims.
• Biosimilar risk does not apply.
• Paragraph IV risk depends on any currently listed, unexpired Orange Book patents.
• Commercial opportunities are concentrated in generic supply, private label, improved patient acceptability, and reliable manufacturing.
• A lower-grease vehicle may offer differentiation, but it increases comparability and regulatory risk.

FAQs About Diflorasone Diacetate Ointment Excipient Strategy

Is diflorasone diacetate ointment an oil-based product?

Yes. The conventional ointment uses a hydrophobic base, principally white petrolatum and mineral oil.

Does diflorasone diacetate ointment require a preservative?

A fully anhydrous ointment generally does not require a conventional antimicrobial preservative, but the final decision depends on water activity, manufacturing controls, packaging, and regulatory evaluation.

Can a company patent a new diflorasone diacetate ointment?

Potentially. Patentable subject matter may include a non-obvious formulation, delivery system, manufacturing process, package, or treatment method. A simple substitution of common ointment excipients is unlikely to provide strong patent protection.

Is diflorasone diacetate ointment suitable for a 505(b)(2) product?

A 505(b)(2) pathway may be relevant for a materially different formulation, dosage form, delivery system, or labeling profile. A conventional equivalent ointment would normally be evaluated for the ANDA pathway.

What is the strongest commercial differentiator for a generic diflorasone diacetate ointment?

Consistent supply is likely to be the strongest immediate differentiator. A lower-grease, easy-spread vehicle or improved dispensing package can support longer-term differentiation if it demonstrates comparable product performance.

References

1. DailyMed. (n.d.). Diflorasone diacetate ointment, 0.05%: Prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process.
3. U.S. Food and Drug Administration. (2022). Acyclovir topical cream and ointment products: Guidance for industry and related topical dermatological product development guidance.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Washington, DC: U.S. Department of Health and Human Services.
5. U.S. Food and Drug Administration. (2016). Physiological and formulation factors affecting bioavailability of topical dermatological drug products. Guidance for industry.